MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
Portfolio Pulse from
MediWound Ltd. announced the publication of Phase III CIDS study results in the Burns Journal, confirming the superiority of NexoBrid® over standard care for pediatric deep thermal burns. NexoBrid is approved for pediatric use in the U.S., E.U., and Japan.
February 25, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MediWound's Phase III study results published in the Burns Journal show NexoBrid's effectiveness in pediatric burn care, potentially boosting its market adoption and sales.
The publication of Phase III study results in a reputable journal confirms the effectiveness of NexoBrid, which is already approved in major markets. This could lead to increased adoption and sales, positively impacting MediWound's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100